<DOC>
	<DOCNO>NCT00606892</DOCNO>
	<brief_summary>To examine effect varenicline subjective , physiological cognitive response intravenous nicotine . Varenicline partial nicotine agonist approve treatment smoke cessation . We predict varenicline treatment modify subjective , physiological cognitive response IV nicotine .</brief_summary>
	<brief_title>Varenicline Nicotine Interactions Humans ( VA )</brief_title>
	<detailed_description>This 2-4 week double-blind , placebo-controlled study . Twenty four male female smoker two 4-day treatment period , randomize varenicline ( 1 mg/day ) placebo . During first 3 day treatment period , smoker daily clinic visit receive study medication . On Day 4 , subject come laboratory , receive ascend dos intravenous ( IV ) nicotine ( 0.1 , 0.4 , 0.7 mg per 70kg ) . This procedure allow accurate assessment varenicline effect subjective , physiological cognitive response nicotine . Following washout period , subject cross alternative treatment .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Female male smoker , age 18 55 year History smoke daily past 12 month , least 15 cigarette daily Carbon Monoxide ( Alveolar ) level &gt; 10ppm For woman : pregnant determine pregnancy screening , breast feeding , use acceptable birth control method History heart disease , renal hepatic disease medical condition physician investigator deems contraindicate subject study Regular use psychotropic medication ( antidepressant , antipsychotic , anxiolytic ) recent psychiatric diagnosis treatment Axis I disorder include major depression , bipolar affective disorder , schizophrenia panic disorder within past year Current dependence alcohol drug treatment drug alcohol addiction within past 5 year Allergy varenicline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>therapeutic effect</keyword>
</DOC>